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nprotected Left Main Intervention
atient Selection, Operator Technique, and Clinical Outcomes
aul S. Teirstein, MD
a Jolla, California
n the 1980s, early attempts at balloon angioplasty of the unprotected left main coronary artery
UPLM) were associated with poor early outcomes because of coronary dissection, abrupt closure, and
estenosis. Mortality rates as high as 30% at 1 year were reported. In the 1990s, bare-metal stents
elped reduce acute complications, but high rates of repeat revascularization (20% to 30%) were ob-
erved because of restenosis. In the early 2000s, the introduction of drug-eluting stents (DES), with the
romise of vastly reduced rates of restenosis, raised the possibility of improved late outcomes for
PLM patients receiving stents. Although use of DES for UPLM is currently a class III indication in pa-
ients who are candidates for coronary artery bypass graft (CABG), many patients are currently under-
oing this procedure. Published registries indicate the procedural and in-hospital risks are acceptable
nd seem to be the same or lower than the procedural risks of CABG. Unprotected left main ostial and
idshaft lesions have excellent early and midterm outcomes that will likely (although not yet proven)
e similar to those of CABG. Distal left main lesions involving the bifurcation are technically more chal-
enging and associated with a higher rate of late revascularization. Early registry data have not found
xcess mortality in patients receiving DES for UPLM when compared with historical bypass surgery
ata, even when the distal bifurcation is stented. However, current follow-up of stented patients is lim-
ted to 1 year or less. Over the next few years, the results of randomized trials will expand the evi-
ence base available to clinicians caring for this challenging patient group. (J Am Coll Cardiol Intv
008;1:5–13) © 2008 by the American College of Cardiology Foundationm
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(he left main coronary artery’s critical importance
o coronary circulation has focused attention on
his specific anatomical subgroup for decades. In
he early 1970s, coronary artery bypass graft
CABG) was found to improve late survival in
atients with significant left main stenosis in com-
arison with medical therapy (1–3). Once CABG
ecame the standard of care for left main disease, a
istinction between protected—by at least 1 patent
ypass graft to the left coronary artery—and un-
rotected left main coronary arteries (UPLM)—no
atent bypass graft to the left coronary artery—was
rom the Division of Cardiology and Interventional Cardiology, Scripps
linic, La Jolla, California. Dr. Teirstein is a consultant for Cordis,
oston Scientific, Abbott, Medtronic, and Conor; receives royalties (not
n drug-eluting stents) from Boston Scientific; and owns equity in
ediVas.d
anuscript received November 16, 2007; revised manuscript received
ovember 28, 2007, accepted December 3, 2007.ade. This review is confined to the treatment of
PLM disease. In the 1980s, early attempts at
alloon angioplasty of the UPLM were associated
ith poor early outcomes because of coronary
issection, abrupt closure, and restenosis. Mortal-
ty rates as high as 30% at 1 year were reported
4–6). In the 1990s, bare-metal stents were intro-
uced and soon were used to treat UPLM disease.
everal small registries found a low rate of proce-
ural complications, but rates of repeat revascular-
zation of 20% to 30% because of restenosis were
onsidered unacceptable (7–12). Early bare-metal
tent registries for UPLM also found high mortal-
ty rates, particularly in high-risk patients, such as
atients with acute coronary syndromes and poor
eft ventricular function. Importantly, high-risk
ubgroups often presented with late sudden death
11,13). In the early 2000s, the introduction of
rug-eluting stents (DES), with the promise of
v
b
g
E
C
e
e
p
(
6
r
(
c
b
w
a
c
i
c
l
t
c
p
i
s
m
p
s
m
f
a
n
m
a
a
T
s
d
a
u
w
a
r
f
a
s
h
e
a
c
f
r
l
c
o
A
a
C
b
D
I
u
L
d
P
s
S
s
T
r
T
r
U
m
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 1 , 2 0 0 8
F E B R U A R Y 2 0 0 8 : 5 – 1 3
Teirstein
DES for Unprotected Left Main Disease
6astly reduced rates of restenosis (14–17), raised the possi-
ility of improved late outcomes in this challenging patient
roup.
arly Clinical Results of DES for UPLM Stenosis
linical outcomes after treatment of UPLM disease with
ither the sirolimus-eluting stent (SES) or the paclitaxel-
luting stent (PES) from nearly 20 small registries have been
ublished. Results reported in these registries vary widely
18–40). As depicted in Table 1, cardiac mortality between
and 12 months ranges from 0% to 11%. Target lesion
evascularization (TLR) or target vessel revascularization
TVR) rates range from 2% to 38%. This wide variation in
linical outcome seems largely attributable to variation in
oth patient selection and procedural technique.
Although results after UPLM stenting are usually re-
ported as a single, homogeneous
subgroup of coronary artery dis-
ease, in reality, UPLM encom-
passes a wide spectrum of dis-
ease states. Outcomes will be
particularly dependent on lesion
location. Left main disease can
be confined solely to the left
main ostium or to the midshaft,
regions technically not difficult
to treat with a single stent,
where excellent outcomes can be
expected. In contradistinction,
UPLM disease can be located
distally, involving the ostium of
the left anterior descending
(LAD) and/or circumflex arter-
ies, resulting in a much more
technically complex procedure,
often requiring double stenting,
ith expected less favorable long-term outcomes. Addition-
lly, the UPLM vessel can be large in diameter and free of
alcium, which is associated with better outcomes, or small
n diameter and contain significant quantities of calcium,
Table 1. DES for the Unprotected Left Main Coronary Artery
Park et al.
(20)
Chieffo et al.
(19)
Valg
Patients, n 102 85
Distal lesion location (%) 71 81
Cardiac mortality, 6–12 months (%) 0 3.5
Angiographic follow-up (%) 84.3 NR
Angiographic restenosis (%) 7* 19†
TLR or TVR (%) 2§ 18.8
*Follow-up angiography at 6months.†Follow-up angiography at 4 to 8months.‡Follow-up angiog
from Baim et al. (39).
bbreviations
nd Acronyms
ABG  coronary artery
ypass graft
ES  drug-eluting stent(s)
VUS  intravascular
ltrasound
AD  left anterior
escending artery
ES  paclitaxel-eluting
tent(s)
ES  sirolimus-eluting
tent(s)
LR  target lesion
evascularization
VR  target vessel
evascularization
PLM  unprotected left
ain coronary arteryDES drug-eluting stent; NR not reported.reating a technically demanding procedure that results in
ess favorable short-term and long-term outcomes.
Another important differentiating patient characteristic is
he presence of significant distal disease in the LAD and/or
ircumflex arteries, requiring multilesion intervention. The
resence of multiple downstream lesions will obviously
ncrease procedural complexity and also increase the risk for
ubsequent revascularization. Finally, any study of UPLM
ust take patient comorbidity into consideration. Often,
atients are refused CABG for UPLM disease because of
erious comorbidities (i.e., stenting in the setting of acute
yocardial infarction, advanced age, poor left ventricular
unction, coexisting malignancy, renal failure, and porcelain
orta) that will also impact long-term outcome after coro-
ary stenting. Thus, published studies of UPLM stenting
ust be viewed in the context of the clinical, angiographic,
nd procedural (especially, number of stents needed) char-
cteristics of patients enrolled in each specific study.
Figure 1 shows a patient with midshaft UPLM stenosis.
his is one of the most straightforward UPLM lesions for
tenting, and an excellent outcome was obtained after
eployment of a single stent in the shaft of the left main
rtery. A recent multicenter registry of 147 patients (35)
ndergoing UPLM stenting of ostial or midshaft lesions
ith SES (n 107) or PES (n 40) found excellent results
t midterm clinical follow-up (886  308 days). In this
egistry, cardiac mortality was 0% in-hospital and 2.7% at
ollow-up. Cardiac mortality was 0% in 87 patients judged
t low risk because of a EuroSCORE 6 and/or Parsonnet
core 13 (41,42), but was 6.7% in 60 patients with
igh-risk scores. With over a 2-year mean follow-up in the
ntire group, TVR was only 4.7%. Thus, patients with ostial
nd midshaft UPLM lesions seem to have excellent out-
omes after DES. These outcomes are likely to compare
avorably with surgical outcomes, but we await the results of
andomized trials before drawing conclusions.
In contradistinction to patients with ostial or midshaft
esions, patients with distal bifurcation lesions are more
hallenging to treat and have less favorable long-term
utcomes. The initial Scripps Clinic UPLM experience
et al. Lee et al.
(28)
Price et al.
(32)
Migliorini et al.
(30)
Erglis et al.
(38)
50 50 101 53
60 94 87 81
4 2 11 2
42 98 96 100
NR 44‡ 16* 6*
 13 38§ 14 2§
t 3 and 9months.§Target lesion revascularization (TLR). Target vessel revascularization (TVR). Dataimigli
(37)
95
65
11
NR
NR
6.3
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7ontained patients with predominantly distal bifurcation
isease (32). In this small, 50-patient registry using SES for
PLM, 94% of patients had disease at the distal left main
ocation. Instead of a single stent treating the left main
nd/or ostium of the LAD or circumflex artery, multiple
tents were used in 84% of patients. This registry found a
-month cardiac mortality rate of only 2%, but a TLR rate
f 38%. Interestingly, the high TLR rate was also driven by
n extremely high rate of angiographic follow-up. Fully 98%
f patients had a follow-up angiogram at 3 and/or 9 months.
sing an ischemia-driven TLR definition (patient has signs
r symptoms of coronary ischemia), TLR was only observed
n 14% of patients. This emphasizes the confounding
mpact of the occulostenotic reflex when interpreting results
f UPLM stenting studies. Patients undergoing stenting of
PLM are often compliant with protocol-mandated sur-
eillance angiography, and interventionalists are likely to
ave a low threshold to intervene when clinically silent
estenosis is found in the left main vessel or the ostium of
Figure 1. Critically Narrowed Midshaft Stenosis in an 83-Year-Old Man Wit
This is one of the most straightforward unprotected left main coronary artery
comes were achieved after implantation of a single 8-mm-long drug-eluting st
Figure 2. A 54-Year-Old Man With Favorable UPLM Distal Bifurcation Lesio
The lesion involves the distal left main vessel (arrow), but there is very little in
the distal left main vessel into the left anterior descending artery (arrow), cros
the circumﬂex was treated with a ﬁnal kissing balloon inﬂation, providing an excellehe circumflex artery or LAD because of the large quantity
f myocardial territory perceived at risk.
Interestingly, a universal finding of the many DES
PLM registries is the predominance of restenosis occur-
ing at the ostium of the left circumflex artery, especially in
atients initially presenting with distal bifurcation disease
nd treated with 2 stents. The cause of this restenosis
redilection for the ostium of the circumflex is unknown,
ut may be attributable to the sharp bend often taken by the
ircumflex artery in this location, which could result in lack
f stent and drug apposition to the vessel wall, or perhaps
ven stent fracture.
Figure 2 shows a relatively favorable UPLM distal bifur-
ation lesion. This 54-year-old patient with unstable angina
as a lesion involving the distal left main vessel but very
ittle involvement of the ostium of the circumflex artery. A
ingle stent can be deployed from the distal left main vessel
nto the LAD crossing over the circumflex artery (the
rossover technique). This lesion can be contrasted with the
table Angina
s for stenting (A). The arrow shows the stenosis. Excellent angiographic out-
addition to stenting of the mid left anterior descending artery (B).
ment of the ostium of the circumﬂex (A). A single stent was deployed from
ver the circumﬂex artery (the crossover technique). Mild plaque shift intoh Uns
lesionn
volve
sing ont angiographic result (B). UPLM  unprotected left main coronary artery.
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8atient depicted in Figure 3. Here we see a highly stenotic,
alcified UPLM lesion involving the distal left main and
oth left coronary branch ostia in a 92-year-old woman with
oncomitant critical aortic valve disease. This patient was
onsidered at such high risk that an intra-aortic balloon
ump was placed prophylactically and 2 stents spanning the
eft main vessel and each branch were simultaneously
eployed (the double-barrel technique). This patient is at
articularly high risk for restenosis, especially at the circum-
ex ostium.
There have been several small published registries com-
aring UPLM DES with CABG. Lee et al. (28) compared
73 consecutive patients at a single institution undergoing
oth procedures. The investigators found a nonsignificantly
igher mortality rate at 6 months with CABG compared
ith DES (11% vs. 4%). Conversely, the rate of TVR was
onsignificantly higher in DES patients (7% vs. 1%).
imilarly, Chieffo et al. (22) compared 107 DES to 142
ABG patients in a nonrandomized registry. At 1 year,
eath also trended higher in CABG patients (6.4% vs.
.8%), and TVR was similarly higher in DES patients
19.6% vs. 3.6%).
Recently, a meta-analysis of 1,278 patients from 17 pub-
ished studies undergoing DES for UPLM disease was re-
orted (40). As previously highlighted, there was wide varia-
ion among trials with respect to baseline patient and
ngiographic characteristics. The overall midterm results (me-
ian follow-up was 10 months, range 6 to 19 months) found a
ortality rate of 5.5% and TVR rate of 6.5%. Although these
esults are encouraging, it must be emphasized that there was
ubstantial variation in outcome among these 17 trials (Figs. 4
nd 5). The 5.5% pooled risk of late mortality reported in the
eta-analysis may not apply to a specific patient in whom
Figure 3. Pre-Procedure Angiogram From a 92-Year-Old Woman With Critic
This critically narrowed distal left main lesion (A) involves both the left anterio
of the branch vessels, 2 stents were deployed simultaneously (arrow) using th
this lesion is at higher risk for restenosis, particularly at the circumﬂex ostiumreatment options are being considered. tatient Selection
lthough numerous patients throughout the world are
urrently undergoing DES for UPLM, it should be empha-
ized that the current American College of Cardiology
ACC)/American Heart Association (AHA)/Society for
ardiovascular Angiography and Interventions (SCAI)
ractice Guidelines for percutaneous coronary interventions
learly categorize UPLM stenting as a class III indication
43) (meaning it should not be undertaken) unless the
atient is not a candidate for bypass surgery. However, the
evel of evidence provided is C (i.e., only consensus opinion
f experts, case studies, or standard-of-care). Currently,
ithout randomized trials, there is little evidence-based
edicine available to guide patient care decisions. There-
ore, the discussion that follows is the author’s opinion
ased on consideration of available registry data and per-
onal experience.
Before selecting a patient for UPLM intervention, one
hould be certain that left main disease exists. This is
articularly important if a patient has an ostial main lesion
vident angiographically only in the cranial angulation. This
rojection is notorious for artifactually enhancing the ap-
earance of left main vessel stenoses. Intravascular ultra-
ound (IVUS) is the ideal method for confirming the
resence of significant left main disease and also for guiding
election of stent size, assessing the presence of calcification,
nd documenting the involvement of the distal left main
essel and its branches. One commonly used IVUS thresh-
ld for significant left main disease is a minimal luminal area
f 6.0 mm2 (44); another is 7.5 mm2 (45).
Informed consent is essential when considering patients
or UPLM stenting. Patients who are not candidates for
urgery because of comorbidities or poor distal targets are
tic Stenosis in Preparation for Percutaneous Aortic Valve Implantation
ending artery and circumﬂex ostia (arrow). To reduce the risk of closing one
ble-barrel technique (B). The ﬁnal angiographic result was excellent (C), but
).al Aor
r desc
e douhe least controversial to treat. These patients should be
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9nformed that although stenting may be their best option,
he long-term outcome after DES is, at present, poorly
haracterized. Patients who are acceptable candidates for
ABG are extremely challenging to consent. Usually these
atients request stenting instead of bypass surgery, with
arying degrees of conviction. It is important to spend
Figure 4. Recent Meta-Analysis of 1,278 Patients Undergoing UPLM DES F
At a median of 10 months of follow-up, the mortality risk was only 5.5% (rang
the follow-up time was relatively short. Data from Biondi-Zoccai et al. (40). CI 
coronary artery.
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Figure 5. Recent Meta-Analysis of 1,278 Patients Undergoing UPLM DES F
At a median of 10 months of follow-up, the target vessel revascularization (TV
Note the extremely wide variation among the different registries. Data from Biondi-Zonsiderable time with this patient group, going over the
ES procedure and its potential risks and benefits in
omparison with CABG. Ad-hoc stenting (46), wherein the
atient gives consent while remaining on the catheterization
able after the diagnostic examination, should be avoided.
he importance of the UPLM artery should be graphically
5 Registries
to 7.7%). However, there was signiﬁcant variation between registries, and
ﬁdence interval; DES  drug-eluting stents; UPLM  unprotected left main
44.0
18.8
30 45 60
Rate of mid-term TVR (%)
.7-9.2)
5 Registries
was only 6.5% (range 3.7% to 9.2%).rom 1
e 3.4%
con12.1
15
6.5 (3
rom 1
R) risk
occai et al. (40). Abbreviations as in Figure 4.
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10escribed to the patient. It is helpful to use an analogy, such
s “the trunk of the tree,” to visually emphasize the impor-
ance of this lesion’s location. It is critical to make it very
lear to the patient that UPLM stenting is not currently
onsidered the standard-of-care by practice society guide-
ines and that the dataset we have regarding midterm and
ong-term outcomes is limited. It is often helpful to have a
ardiovascular surgeon speak independently with the pa-
ient, as well as another cardiologist who is not an inter-
entionalist. However, it is worth noting that having mul-
iple physicians provide multiple opinions to a patient can
lso confuse some patients, upsetting them and making the
ecision process more difficult. The requirement for routine
ollow-up surveillance angiography must be explained and
greed to by the patient. Although some physicians do not
elieve routine surveillance angiography is warranted after
PLM stenting, this author strongly believes that follow-up
ngiography at 3 to 9 months is important, particularly in
ight of the limited data we have concerning late outcomes.
urveillance angiography after UPLM stenting is currently
n ACC/AHA/SCAI Practice Guideline Class IIa (mean-
ng it is favored) Recommendation (43).
One UPLM patient subgroup in whom DES might
isely be avoided are patients who have heavily calcified left
ain, ostial LAD, and/or circumflex coronary arteries and
re otherwise good candidates for bypass surgery. These
esions are particularly challenging for percutaneous interven-
ion and should be avoided even if a patient insists on DES.
inally, it should be noted that patients receiving DES for
PLM must be able to take dual antiplatelet therapy for a
inimum of 12 months per current ACC/AHA/SCAI
ractice Guidelines for DES (43). If possible, a longer
uration of antiplatelet therapy may be advantageous.
perator Technique
eft main ostial and midshaft lesions. Although ostial and
idshaft left main vessel lesions are technically straightfor-
ard, there are some procedural caveats. Pre- and post-
rocedural IVUS is helpful for judging the degree of
alcification, stent diameter selection, final stent expansion,
nd stent apposition, and for confirming the absence of
tent edge dissection. In the U.S., the currently available
ES can be expanded to 4.75 mm and the PES can be
xpanded to 4.25 mm. An intra-aortic balloon pump is
arely needed for ostial and midshaft lesions, but should be
onsidered in patients who present with relative hypoten-
ion (i.e., systolic blood pressure 110 mm Hg), poor left
entricular function, and/or a totally occluded right coro-
ary artery. Platelet glycoprotein IIb/IIIa inhibition should
lso be considered. Occasionally, a patient will have an
xtremely large diameter left main coronary vessel that is
4.75 mm. In these patients, in whom a DES of theecessary size is not available, consideration can be given to smplanting a large-diameter bare-metal stent. There are no
ata describing the outcome after large-diameter bare-metal
tents in UPLM lesions. However, in other native vessel
esion locations, large-diameter bare-metal stents are asso-
iated with low restenosis rates. As with DES, surveillance
ngiography of a bare-metal stent is also extremely
mportant.
istal left main bifurcation involvement. Patients with distal
eft main disease involving the ostium of the LAD and/or
ircumflex artery are the most technically difficult to treat
ith stents. These patients often have significant coronary
isease downstream from the left main vessel, which should
e taken into consideration when making a decision be-
ween DES and CABG. When approaching these patients
ith DES, it is helpful to stent all of the downstream lesions
rst because stenting the left main vessel may make access-
ng the downstream lesions more difficult. In these patients,
ne should have a lower threshold for using an intra-aortic
alloon pump, particularly if the systolic blood pressure is
110 mm Hg, the right coronary artery is occluded, left
entricular function is impaired, or the left main, LAD,
nd/or circumflex artery are significantly calcified. Heavily
alcified UPLM arteries may require pre-treatment with
otational atherectomy, which increases procedural risk.
hese factors increase procedural risk and reduce long-term
uccess and must be taken into consideration during the
atient selection process.
From the available registry data, it seems that restenosis
nd repeat revascularization rates are profoundly lower if
nly 1 stent is used when treating the distal left main
ifurcation (18–40). Provided the risk of closing the side
ranch is low, the currently favored technique is the provi-
ional approach of stenting across the distal bifurcation,
sually into the LAD. Often, the circumflex must be
re-dilated to avoid plaque shift and vessel shutdown with
tent deployment. After stenting across the branch vessel,
he branch will usually need to be rescued by recrossing with
guidewire and performing simultaneous kissing balloon
nflation in both the stent and the branch vessel. Most
nterventionalists will perform a final kissing inflation even
f the branch ostium is not compromised after stent implan-
ation to widen the stent struts that cross the large branch
essel. Rarely, the ostium to the circumflex artery is heavily
iseased with minimal disease of the LAD ostium, neces-
itating crossing over the LAD and stenting from the left
ain into the circumflex artery.
Deploying 2 stents in the distal left main vessel should be
ndertaken only when the operator strongly believes that
he probability of acute closure of one of the branches is very
igh (i.e., the lesion shown in Figure 3). Faced with this
ituation, any 1 of the well-described double stent tech-
iques (i.e., a double barrel, crush, T-stent, or modified
-stenting with intentional protrusion of the side-branchtent within the main vessel stent—TAP stenting) can be
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11sed (47–59). When double stents are used, a final simul-
aneous inflation of both stents (kissing balloon inflation) at
igh pressure (16 atm) with noncompliant balloons is
onsidered critical to optimize outcomes. Whatever tech-
ique is chosen, a final examination using IVUS should be
erformed to ensure adequate stent expansion, complete
tent strut apposition to the vessel wall, and absence of
eri-stent dissection.
urveillance angiography. Although controversial, this au-
hor believes 3- to 9-month surveillance angiography is
mportant to rule out the possibility of restenosis presenting
s sudden death. Although presently unproven, noninvasive
urveillance with CT angiography may have a future role for
he follow-up of UPLM stents. Unfortunately, routine
urveillance angiography is likely to result in a higher rate of
VR; however, it seems prudent in light of our limited data
egarding late mortality in this patient subgroup. When
erforming surveillance angiography, 1 caveat is to be aware
f the potential for pseudostenosis at the ostium of the left
ircumflex artery. In patients treated with double stenting of
distal left main bifurcation, we and others have occasion-
lly observed the angiographic appearance of a high-grade
stial circumflex stenosis that is not present when assessed
ith IVUS. This is likely because of the quantity of metal at
he bifurcation, perhaps coupled with eccentric stent expan-
ion (Fig. 6). It is important to use IVUS to rule out a
seudostenosis in this location and to avoid unnecessary
epeat intervention, particularly in asymptomatic patients
ndergoing surveillance angiography.
When true in-stent restenosis of the unprotected left
ain vessel is observed at follow-up angiography, the results
hould be discussed with the patient in detail. If the patient
s a candidate for CABG, the potential benefits and risks of
ABG therapy versus percutaneous intervention should be
Figure 6. Bifurcation Stenting of a UPLM 5 Months Earlier
Follow-up angiography (left), when viewed in the left anterior oblique and ca
ostium. However, intravascular ultrasound (right) showed no important stenos
(arrows). The patient was asymptomatic with a fractional ﬂow reserve after in
was not treated. Image courtesy of Dr. Antonio Columbo, not previously publince again explained. Usually left main in-stent restenosis is ireated with repeat balloon angioplasty; stents are only
dded if the restenosis occurs at a stent margin. If repeat
ntervention is undertaken, further surveillance angiography
s strongly recommended.
he future. At present, UPLM DES is controversial be-
ause there is so little scientific evidence to support it. Over
he next several years, results of randomized trials compar-
ng DES to CABG in this patient subset will become
vailable. The SYNTAX (SYNergy Between Percutaneous
oronary Intervention With TAXus and Cardiac Surgery)
rial has completed enrollment, and results should be
vailable over the next 1 to 2 years. This large, randomized
rial of surgery versus DES in patients with UPLM and/or
-vessel disease has a pre-specified UPLM subgroup con-
aining 710 randomized patients (60). This trial, along with
ther randomized trials, should provide important informa-
ion, particularly with respect to comparative late mortality
nd the need for future revascularization. It will be impor-
ant to analyze the results of these trials in the context of the
esion subtype (i.e., ostial, midshaft, and distal location) and
he procedural stenting techniques used.
It should be noted that current DES technology has not
een directed at UPLM intervention. If evidence accumu-
ates indicating that this patient subgroup benefits from
ES, dedicated UPLM DES technology will likely be
eveloped. We are especially in need of a dedicated bifur-
ation DES stent with the dimensional requirements suited
o the UPLM. For ostial and midshaft lesions, we are in
eed of a larger-diameter DES as well as a shorter-length
ES, consistent with the dimensions of this vessel.
onclusions
lthough DES for UPLM is currently a class III indication
rojection, showed the appearance of an important stenosis at the circumﬂex
no neointimal hyperplasia, but instead, an eccentrically expanded stent
nary adenosine of 0.92. This pseudostenosis in this asymptomatic patient
UPLM  unprotected left main coronary artery.udal p
is and
tracoron patients who are candidates for CABG, many patients are
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12urrently undergoing this procedure. Published registries
ndicate the procedural and in-hospital risks are acceptable
nd probably the same or lower than the procedural risks of
ABG. Unprotected left main ostial and midshaft lesions
ave excellent early and midterm outcomes that will likely
although yet unproven) be similar to those of CABG.
istal left main vessel lesions involving the bifurcation are
echnically more challenging and are associated with a
igher rate of late revascularization. Surveillance angiogra-
hy of patients undergoing UPLM DES, although not
niversally advocated, seems to be a reasonable method of
inimizing the chance of a restenosis presenting as sudden
eath. There are many technical caveats to UPLM stenting.
mproved technology, especially dedicated left main bifur-
ation stents, are needed. Early registry data have not found
xcess mortality in patients receiving DES for UPLM when
ompared with historical bypass surgery data. However, as
et, we have only early, 6-month to 1-year, follow-up of
egistry patients, and randomized trial results are not avail-
ble. Over the next 1 to 2 years, the results of randomized
rials will likely inform and transform the treatment of this
mportant patient group.
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